Résumé :
|
[BDSP. Notice produite par INIST-CNRS 8R0xrqIq. Diffusion soumise à autorisation]. The authors investigated associations of serum phospholipid n-3 and n-6 polyunsaturated fatty acids (PUFAs) and frans-fatty acids with prostate cancer risk, and whether myeloperoxidase G-463A (rs2333227) modified the associations in the Carotene and Retinol Efficacy Trial (CARET) (Seattle, Washington ; Irvine, California ; New Haven, Connecticut ; San Francisco, California ; Baltimore, Maryland ; and Portland, Oregon, 1985-2003). Prerandomization sera were assayed for fatty acids among 641 men with incident prostate cancer (368 nonaggressive and 273 aggressive (stage III/IV or Gleason score>=7)) and 1,398 controls. Overall, dihomo-gamma-linolenic (quartiles 4 vs. 1 : odds ratio (OR)=0.66,95% confidence interval (CI) : 0.49,0.95 ; Ptrend=0.024) and docosatetraenoic (OR=0.69,95% CI : 0.46,1.02 ; Ptrend=0.011) acids were inversely associated with nonaggressive and aggressive prostate cancer risks, respectively. Among men with MPO GG, the genotype upregulating oxidative stress, quartiles 4 versus 1 eicosapentaenoic plus docosahexaenoic acids were suggestively associated with an increased risk of aggressive prostate cancer (OR=1.66,95% CI : 0.95,2.92 ; Ptrend=0.07). However, the association was the inverse among men with MPO GA/AA genotypes (Pinteraction=0.011). Interactions were also observed for docosapentaenoic acid, total n-3 PUFAs, and arachidonic acid. MPO GA/AA vs. GG was associated with a 2-fold increase in aggressive prostate cancer risk among men with low (quartile 1) n-3 PUFAs. This study adds important evidence linking oxidative stress with prostate carcinogenesis.
|